Loading clinical trials...
Loading clinical trials...
First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia.
Conditions
Interventions
MEN1112
Locations
29
Belgium
Antwerp, Belgium
Brussels, Belgium
Liège, Belgium
Roeselare, Belgium
Yvoir, Belgium
Grenoble, France
Start Date
December 1, 2014
Primary Completion Date
April 9, 2021
Completion Date
April 9, 2021
Last Updated
August 12, 2024
NCT04716452
NCT06459024
NCT05190471
NCT06532084
NCT05546580
NCT06125652
Lead Sponsor
Menarini Group
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions